447 filings
Page 4 of 23
6-K
em4jzfil5 oa4z
13 Mar 23
Current report (foreign)
9:00am
6-K
l8jr3 4pp46rg2ba16
21 Feb 23
Current report (foreign)
8:06am
6-K
w9ny7 fskzdoc
15 Feb 23
Current report (foreign)
4:30pm
6-K
ejjbfl
15 Feb 23
Current report (foreign)
8:05am
6-K
hrrsi1irgagjt0s
13 Feb 23
Current report (foreign)
8:05am
6-K
6njnvnvlnbe3
10 Nov 22
Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of Nomacopan for the Treatment of Pediatric HSCT-TMA
4:44pm
424B3
d630ks5sb7d5dx n7lq
9 Nov 22
Prospectus supplement
4:11pm
EFFECT
qaqiqy
9 Nov 22
Notice of effectiveness
12:15am
6-K
tx6xqzinki5ptd
8 Nov 22
Akari Therapeutics Announces the Appointment of John F. Neylan, III, MD as Executive Vice President, Chief Medical Officer
4:34pm
CORRESP
zf7ltv
7 Nov 22
Correspondence with SEC
12:00am
F-1/A
bqrwbq
4 Nov 22
Registration statement (foreign) (amended)
5:00pm
6-K
5p6zgxwxm6e1i k5gsma
28 Oct 22
Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification
4:34pm
UPLOAD
5zwwm ou6sqlm
19 Oct 22
Letter from SEC
12:00am
F-1
47uydm3fc4z691wq1
12 Oct 22
Registration statement (foreign)
4:31pm
6-K
0dmw tu213lsrjdim
27 Sep 22
Current report (foreign)
4:30pm
D
q3cic9znx gvvdmg
27 Sep 22
$12.84M in options / securities to be acquired, sold $12.84M, 21 investors
4:16pm
424B5
5xjr7h
14 Sep 22
Prospectus supplement for primary offering
12:19pm
6-K
q79f14 sasizdg2i
14 Sep 22
Akari Therapeutics Announces $12.75 Million Registered Direct Offering
12:02pm
6-K
yqcmbz
1 Aug 22
Current report (foreign)
5:00pm
6-K
py8 4u11fk9n
29 Jul 22
Current report (foreign)
5:00pm